Clinical trials portrayed in Table 2 assess HSP70-based approaches like vaccines, inhibitors and antibodies across various cancers, investigating its impact on immune responses, tumour regression and diagnostic potential for circulating tumour cells (CTCs). Here, HSPA1A is linked to neoplasm.